SUTRO BIOPHARMA, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
SUTRO BIOPHARMA, INC. (STRO) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $2.01 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-12
- SUTRO BIOPHARMA, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $2.01M, a 61.81% decline year-over-year.
- SUTRO BIOPHARMA, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $1.56M, a 71.79% decline year-over-year.
- SUTRO BIOPHARMA, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $1.55M, a 76.29% decline year-over-year.
- SUTRO BIOPHARMA, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $5.26M, a 14.55% decline year-over-year.
- SUTRO BIOPHARMA, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $14.01M, a 43.26% decline from fiscal 2024.
- SUTRO BIOPHARMA, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $24.69M, a 0.89% decline from fiscal 2023.
- SUTRO BIOPHARMA, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $24.91M, a 5.31% decline from fiscal 2022.
- SUTRO BIOPHARMA, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $26.30M, a 13.18% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.01M 10-Q · filed 2026-08-12 | $3.57M derived: sum of 2 quarters · filed 2026-08-12 | ||
| 2026-03-31 | $1.56M 10-Q · filed 2026-08-12 | |||
| 2025-12-31 | $14.01M 10-K · filed 2026-03-23 | |||
| 2025-09-30 | $1.55M 10-Q · filed 2025-11-06 | $6.82M derived: sum of 2 quarters · filed 2026-08-12 | $12.35M derived: sum of 3 quarters · filed 2026-08-12 | |
| 2025-06-30 | $5.26M 10-Q · filed 2026-08-12 | $10.80M derived: sum of 2 quarters · filed 2026-08-12 | ||
| 2025-03-31 | $5.54M 10-Q · filed 2026-08-12 | |||
| 2024-12-31 | $24.69M 10-K · filed 2026-03-23 | |||
| 2024-09-30 | $6.54M 10-Q · filed 2025-11-06 | $12.70M derived: sum of 2 quarters · filed 2025-11-06 | $18.77M derived: sum of 3 quarters · filed 2025-11-06 | |
| 2024-06-30 | $6.16M 10-Q · filed 2025-11-06 | $12.23M derived: sum of 2 quarters · filed 2025-11-06 | ||
| 2024-03-31 | $6.07M 10-Q · filed 2025-11-06 | |||
| 2023-12-31 | $24.91M 10-K · filed 2025-03-13 | |||
| 2023-09-30 | $6.00M 10-Q · filed 2024-11-13 | $12.66M derived: sum of 2 quarters · filed 2024-11-13 | $18.68M derived: sum of 3 quarters · filed 2024-11-13 | |
| 2023-06-30 | $6.66M 10-Q · filed 2024-11-13 | $12.68M derived: sum of 2 quarters · filed 2024-11-13 | ||
| 2023-03-31 | $6.02M 10-Q · filed 2024-11-13 | |||
| 2022-12-31 | $26.30M 10-K · filed 2025-03-13 | |||
| 2022-09-30 | $6.78M 10-Q · filed 2023-11-13 | $13.48M derived: sum of 2 quarters · filed 2023-11-13 | $20.45M derived: sum of 3 quarters · filed 2023-11-13 | |
| 2022-06-30 | $6.70M 10-Q · filed 2023-11-13 | $13.67M derived: sum of 2 quarters · filed 2023-11-13 | ||
| 2022-03-31 | $6.97M 10-Q · filed 2023-11-13 | |||
| 2021-12-31 | $23.24M 10-K · filed 2024-03-25 | |||
| 2021-09-30 | $6.50M 10-Q · filed 2022-11-08 | $12.40M derived: sum of 2 quarters · filed 2022-11-08 | $16.35M derived: sum of 3 quarters · filed 2022-11-08 | |
| 2021-06-30 | $5.91M 10-Q · filed 2022-11-08 | $9.86M derived: sum of 2 quarters · filed 2022-11-08 | ||
| 2021-03-31 | $3.95M 10-Q · filed 2022-11-08 | |||
| 2020-12-31 | $11.92M 10-K · filed 2023-03-30 | |||
| 2020-09-30 | $3.11M 10-Q · filed 2021-11-10 | $6.12M derived: sum of 2 quarters · filed 2021-11-10 | $8.83M derived: sum of 3 quarters · filed 2021-11-10 | |
| 2020-06-30 | $3.01M 10-Q · filed 2021-11-10 | $5.72M derived: sum of 2 quarters · filed 2021-11-10 | ||
| 2020-03-31 | $2.71M 10-Q · filed 2021-11-10 | |||
| 2019-12-31 | $10.31M 10-K · filed 2022-02-28 | |||
| 2019-09-30 | $2.88M 10-Q · filed 2020-11-05 | $5.34M derived: sum of 2 quarters · filed 2020-11-05 | $7.63M derived: sum of 3 quarters · filed 2020-11-05 | |
| 2019-06-30 | $2.46M 10-Q · filed 2020-11-05 | $4.75M derived: sum of 2 quarters · filed 2020-11-05 | ||
| 2019-03-31 | $2.29M 10-Q · filed 2020-11-05 | |||
| 2018-12-31 | $2.87M 10-K · filed 2021-03-18 | |||
| 2018-09-30 | $321.00K 10-Q · filed 2019-11-08 | $553.00K derived: sum of 2 quarters · filed 2019-11-08 | $802.00K derived: sum of 3 quarters · filed 2019-11-08 | |
| 2018-06-30 | $232.00K 10-Q · filed 2019-11-08 | $481.00K derived: sum of 2 quarters · filed 2019-11-08 | ||
| 2018-03-31 | $249.00K 10-Q · filed 2019-11-08 | |||
| 2017-12-31 | $1.39M 10-K · filed 2020-03-16 | |||
| 2016-12-31 | $968.00K 10-K · filed 2019-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 |